biotech / news / / CNBC
Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster" The partnership will enable Novo to better use AI to analyze complex datasets, the company says.
Novo Nordisk has formed a partnership with OpenAI to accelerate drug discovery using AI.
KEY POINTS
- The collaboration aims to analyze complex datasets to identify new drug candidates more efficiently.
- Novo Nordisk expects AI integration to significantly reduce the time from research to patient use.
- The partnership specifically targets faster development of treatments for obesity and diabetes.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →